The emergence of clonal chromosomal abnormalities in Philadelphia-negative cells during treatment with imatinib in patients with Philadelphia-positive chronic myeloid leukemia has been reported. We add information to this issue presenting a series of 29 patients in complete cytogenetic response after imatinib treatment, three of whom developed clonal aberrations.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
L. (purslane) extract ameliorates intestinal inflammation in diet-induced obese mice by inhibiting the TLR4/NF-κB signaling pathway.
Front Pharmacol
January 2025
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR, China.
Background: L. (purslane) is a dietary plant and a botanical drug with antioxidant, antidiabetic, and anti-inflammatory activities. However, the effects of purslane against intestinal-inflammation-associated obesity are yet to be studied.
View Article and Find Full Text PDFDasatinib-Induced Gynecomastia: A Case Report.
Cureus
December 2024
Medical Oncology, Jawaharlal Nehru Medical College, Wardha, IND.
Gynecomastia, the abnormal enlargement of male breast tissue, is a rare side effect associated with dasatinib. This drug is used in the treatment of chronic myeloid leukemia (CML). We present a case of dasatinib-induced gynecomastia in a 52-year-old gentleman with CML who developed bilateral breast enlargement and tenderness after approximately four months of dasatinib treatment.
View Article and Find Full Text PDFPonatinib alleviates non-alcoholic steatohepatitis through TFEB-mediated autophagy.
Front Pharmacol
January 2025
Department of Clinical Pharmacy, Meizhou People's Hospital (Huangtang Hospital), Meizhou, China.
Objective: Non-alcoholic steatohepatitis (NASH) is a progressive liver disease with lipid accumulation, inflammation, and liver fibrosis. Ponatinib, a third-generation tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia, was found to improve metabolic disorders in mice. However, the role of ponatinib in liver inflammation and fibrosis remains to be elucidated.
View Article and Find Full Text PDFCost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in South Africa.
Front Pharmacol
January 2025
Health Economics Unit, School of Public Health, University of Cape Town, Cape Town, South Africa.
Background: The treatment of chronic myeloid leukemia through tyrosine kinase inhibitors (TKIs) has achieved promising efficacy and safety outcomes, however the costs are associated with a substantial economic burden. The objective of this study was to develop a Markov model with a 20-year time horizon to assess the cost effectiveness of TKIs from a public healthcare system perspective in South Africa.
Methods: We constructed a Markov model to compare three strategies in which treatment was initiated with either imatinib, nilotinib, or dasatinib.
Long-term outcomes of chronic myeloid leukemia in children and adolescents - Real world data from a single-institute in Taiwan.
J Formos Med Assoc
January 2025
Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, 704302, Taiwan; Department of Pediatrics, College of Medicine, National Cheng Kung University, Tainan, 701401, Taiwan. Electronic address:
Background/purpose: Tyrosine kinase inhibitors (TKIs) have revolutionized chronic myeloid leukemia (CML) treatment, yet long-term pediatric outcomes and growth effects remain limited. This study describes the long-term efficacy and growth impact of TKIs in children and adolescents with CML.
Methods: We retrospectively reviewed 14 pediatric CML patients treated with TKIs at our institute.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!